BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38288892)

  • 1. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP; Baraliakos X; Lambert RG; Landewé R; Sandoval D; Carlier H; Lisse J; Li X; Hojnik M; Østergaard M
    Lancet Rheumatol; 2022 Sep; 4(9):e626-e634. PubMed ID: 38288892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
    Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis research consortium of Canada scoring system.
    Zhang Y; Guo Z; Zhan Y; Qu J; Lei X
    BMC Musculoskelet Disord; 2022 Jul; 23(1):654. PubMed ID: 35804360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.
    Maksymowych WP; Wichuk S; Dougados M; Jones HE; Pedersen R; Szumski A; Marshall L; Bukowski JF; Lambert RG
    Ann Rheum Dis; 2018 Jan; 77(1):78-84. PubMed ID: 28970212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.
    Pedersen SJ; Poddubnyy D; Sørensen IJ; Loft AG; Hindrup JS; Thamsborg G; Asmussen K; Hendricks O; Nørregaard J; Piil AD; Møller JM; Jurik AG; Balding L; Lambert RG; Sieper J; Østergaard M
    Arthritis Rheumatol; 2016 Feb; 68(2):418-29. PubMed ID: 26414004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation.
    Maksymowych WP; Wichuk S; Dougados M; Jones H; Szumski A; Bukowski JF; Marshall L; Lambert RG
    Arthritis Res Ther; 2017 Jun; 19(1):126. PubMed ID: 28587658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
    Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postpartum Bone Marrow Edema at the Sacroiliac Joints May Mimic Sacroiliitis of Axial Spondyloarthritis on MRI.
    Agten CA; Zubler V; Zanetti M; Binkert CA; Kolokythas O; Prentl E; Buck FM; Pfirrmann CWA
    AJR Am J Roentgenol; 2018 Dec; 211(6):1306-1312. PubMed ID: 30247978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
    Maksymowych WP; Østergaard M; Landewé R; Barchuk W; Liu K; Tasset C; Gilles L; Hendrikx T; Besuyen R; Baraliakos X
    Rheumatology (Oxford); 2022 May; 61(5):2063-2071. PubMed ID: 34352069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis.
    Pedersen SJ; Wichuk S; Chiowchanwisawakit P; Lambert RG; Maksymowych WP
    Arthritis Res Ther; 2014 Apr; 16(2):R100. PubMed ID: 24755322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.
    Braun J; Blanco R; Marzo-Ortega H; Gensler LS; Van den Bosch F; Hall S; Kameda H; Poddubnyy D; van de Sande M; van der Heijde D; Zhuang T; Stefanska A; Readie A; Richards HB; Deodhar A
    Arthritis Res Ther; 2023 May; 25(1):80. PubMed ID: 37194094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Inflammatory and Chronic Structural Damages of Sacroiliac Joint in Patients With Radiographic Axial Spondyloarthritis and Non-Radiographic Axial Spondyloarthritis.
    Tu L; Lin C; Xie Y; Wang X; Wei Q; Zhang Y; Gu J
    Front Immunol; 2021; 12():700260. PubMed ID: 34386008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
    Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of 3 Preliminary MRI Sacroiliac Joint Composite Structural Damage Scores in a 5-year Longitudinal Axial Spondyloarthritis Study.
    Wetterslev M; Østergaard M; Sørensen IJ; Weber U; Loft AG; Kollerup G; Juul L; Thamsborg G; Madsen OR; Møller JM; Pedersen SJ
    J Rheumatol; 2021 Oct; 48(10):1537-1546. PubMed ID: 33858979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
    Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging of Lesions in the Sacroiliac Joints for Differentiation of Patients With Axial Spondyloarthritis From Control Subjects With or Without Pelvic or Buttock Pain: A Prospective, Cross-Sectional Study of 204 Participants.
    Seven S; Østergaard M; Morsel-Carlsen L; Sørensen IJ; Bonde B; Thamsborg G; Lykkegaard JJ; Hendricks O; Jørgensen NR; Pedersen SJ
    Arthritis Rheumatol; 2019 Dec; 71(12):2034-2046. PubMed ID: 31309740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Severity of Sacroiliitis and Extensive Fat Metaplasia Predicts the Progression of Backfill at the Sacroiliac Joint in Patients With Axial Spondyloarthritis.
    Zhang Y; Guo Z; Wang L; Zhan Y; Qu J; Lei X
    Front Immunol; 2022; 13():887470. PubMed ID: 35833133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters.
    Gezer HH; Duruöz MT
    Int J Rheum Dis; 2022 Apr; 25(4):433-439. PubMed ID: 35080124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.